The American Journal of Pharmacy Benefits | July/August 2013

Conference Coverage

The ATS 2013 conference focused on pulmonary care, critical care, sleep medicine, and more.

Drug Trends

We examined the prevalence of use and cost impact of DPP-4 inhibitors and GLP-1 receptor agonists in people with diabetes.

From the Editor

Physicians should work with retail pharmacies to find cost-effective medication strategies for their patients.

Original Research

Using the SEER-Medicare database, we found negative association between Medicare claim processors“related physician's chemotherapy reimbursement and their prescription of granulocyte colony-stimulating factor for non-Hodgkin lymphoma patients.

Patient Advocacy

A tool for organizing patient concerns and comments to ensure that the FDA captures the comprehensive information it needs to integrate patient perspectives throughout the agency's review process.

Specialty Healthcare Benefits Council

With increasing regulatory oversight for sterile compounding and a limited ability to assure the quality of compounded sterile products obtained from external sources, many hospital pharmacies are moving to insource these products.

WEB EXCLUSIVE

Treatment patterns, resource utilization, and healthcare costs associated with guanfacine immediate release versus guanfacine extended release were compared in children and adolescents with attention-deficit/hyperactivity disorder.
Healthcare utilization and costs for patients taking esomeprazole were compared in the 12-month periods before and after exclusion of the proton pump inhibitor from formulary.
This study evaluated the categories, quantities, and prescribers of unused first-fill medications returned through a Drug Enforcement Administration National Drug Take-Back Day event.

More issues

Feature
Opioid Induced Constipation: Considerations When Evaluating Formulary Decisions
Comparative Effectiveness Research: Improving Rheumatoid Arthritis Patient Outcomes with Immunotherapy
$vacMongoViewPlus$